Human survivin is negatively regulated by wild-type p53 and participates in p53-dependent apoptotic pathway
Authors:
- Marnie McGuirkMMMarnie McGuirk
- Tish N HockenberryTHTish N Hockenberry
- Qun WuQWQun Wu
- Hena AsharHAHena Ashar
- Stuart BlackSBStuart Black
- Shu Fen WenSWShu Fen Wen
- Luquan WangLWLuquan Wang
- Paul KirschmeierPKPaul Kirschmeier
- W Robert BishopWBW Robert Bishop
- Loretta L NielsenLNLoretta L Nielsen
- Cecil B PickettCPCecil B Pickett
- 18 April 2002
- journal article
- Published by Springer Nature in Oncogene
- Vol. 21 (17) , 2613-2622
Abstract
Survivin is an inhibitor of apoptosis protein, which is over-expressed in most tumors. Aberrant expression of survivin and loss of wild-type p53 in many tumors prompted us to investigate a possible link between these two events. Here we show that wild-type p53 represses survivin expression at both mRNA and protein levels. Transient transfection analyses revealed that the expression of wild-type p53, but not mutant p53, was associated with strong repression of the survivin promoter in various cell types. The over-expression of exogenous survivin protein rescues cells from p53-induced apoptosis in a dose-dependent manner, suggesting that loss of survivin mediates, at least, in part the p53-dependent apoptotic pathway. In spite of the presence of two putative p53-binding sites in the survivin promoter, deletion and mutation analyses suggested that neither site is required for transcriptional repression of survivin expression. This was confirmed by chromatin immunoprecipitation assays. Further analyses suggested that the modification of chromatin within the survivin promoter could be a molecular explanation for silencing of survivin gene transcription by p53.Keywords
This publication has 38 references indexed in Scilit:
- Binding of c-Myc to chromatin mediates mitogen-induced acetylation of histone H4 and gene activationGenes & Development, 2001
- Development and validation of sensitive assays to quantitate gene expression after p53 gene therapy and paclitaxel chemotherapy using in vivo dosing in tumor xenograft modelsCancer Gene Therapy, 2000
- Direct Examination of Histone Acetylation on Myc Target Genes Using Chromatin ImmunoprecipitationJournal of Biological Chemistry, 2000
- Book reviewEye, 2000
- Expression and Targeting of the Apoptosis Inhibitor, Survivin, in Human MelanomaJournal of Investigative Dermatology, 1999
- p53-Induced Apoptosis as a Safeguard against CancerBiochemical and Biophysical Research Communications, 1999
- What's Up and Down with Histone Deacetylation and Transcription?Cell, 1997
- Adenovirus-Based p53 Gene Therapy in Ovarian CancerGynecologic Oncology, 1995
- Definition of a consensus binding site for p53Nature Genetics, 1992
- Isolation of biologically active ribonucleic acid from sources enriched in ribonucleaseBiochemistry, 1979